Sanyo’s MIR-S100C compact orbital shaker is for use in high humidity and/or elevated CO2 concentration conditions. With the orbital shaker mounted inside the incubator and an independent controller placed externally, the MIR-S100C offers simple, secure operation for cell culture applications within GMP environments.
The MIR-S100C incorporates antibacterial copper alloy stainless steel for the shaker section, with a small window that can be used for spraying disinfectant inside. The controller is a separate unit, preventing humidity from affecting the electrical components and enabling operation to be monitored without opening the incubator.
Revolution speed is adjustable from 40–200rpm and the timer can be set for up to 99.9 hours or continuous operation. A soft start function protects against spillage or foaming of samples inside flasks and test tubes by gradually accelerating at a selectable speed until the preset number of revolutions is reached.
Features include a non-volatile memory facilitating automatic recovery after a power cut, speed error alarm and motor overload protection circuit to ensure security of operation. A maintenance-required indicator is provided for timely replacement of belt and bearings, and therefore more secure continuous operation.
Optional accessories include a platform on which cultures may be placed and clamps and racks for a variety of flasks and tubes.
MIR-S100C offers secure operation for cell culture
For use in high humidity conditions
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months